Add time:09/01/2019         Source:sciencedirect.com

BackgroundAdding the μ-opioid receptor agonist remifentanil to agents used to induce general anaesthesia in electroconvulsive therapy (ECT) can reduce the required doses of induction agents and their unfavourable effects on seizure threshold and quality. However, whether remifentanil has favourable long-term treatment effects in terms of response and remission rates, speed of response and remission, and side-effects has not been studied.

We also recommend Trading Suppliers and Manufacturers of REMIFENTANIL (cas 132875-61-7). Pls Click Website Link as below: cas 132875-61-7 suppliers